In particular, PD-L1 expression was significantly increased in ARID1A-mutated cancers (16, 17), which could lead to impaired tumor immunity, and this might represent a potential mechanism by which ARID1A-deficient tumors escape immune surveillance. This evidence concerns the gene CD274 and cancer.